Evidence map›Paper›PMID 27128622›Full record

ArticlePloS one2016

Combined Id1 and Id3 Deletion Leads to Severe Erythropoietic Disturbances.

Qingshi Zhao, Corey Chang, J Patrick Gonzalez, Kamal Alzahrani, Jessica L Button, Diego Fraidenraich

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Qingshi ZhaoDepartment of Cell Biology and Molecular Medicine, Rutgers Biomedical and Health Sciences, New Jersey Medical School, Newark, New Jersey, United States of America.
Corey ChangDepartment of Cell Biology and Molecular Medicine, Rutgers Biomedical and Health Sciences, New Jersey Medical School, Newark, New Jersey, United States of America.
J Patrick GonzalezDepartment of Cell Biology and Molecular Medicine, Rutgers Biomedical and Health Sciences, New Jersey Medical School, Newark, New Jersey, United States of America.
Kamal AlzahraniDepartment of Cell Biology and Molecular Medicine, Rutgers Biomedical and Health Sciences, New Jersey Medical School, Newark, New Jersey, United States of America.
Jessica L ButtonDepartment of Cell Biology and Molecular Medicine, Rutgers Biomedical and Health Sciences, New Jersey Medical School, Newark, New Jersey, United States of America.
Diego FraidenraichDepartment of Cell Biology and Molecular Medicine, Rutgers Biomedical and Health Sciences, New Jersey Medical School, Newark, New Jersey, United States of America.
Rutgers HealthRutgers, The State University of New Jersey · US

Funding

Rutgers Mass Spectrometry Core for Integrative Neuroscience ResearchP30NS046593 · NINDS · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI LOBEL, PETER · 2004 to 2018
$9.9M
Role of murine induced pluripotent stem cells on the correction of cardiac and skR21HL094905 · NHLBI · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI FRAIDENRAICH, DIEGO · 2009 to 2010
$429k
Nitric oxide pathway requirement for the correction of cardiomyopathy in muscularF31HL117621 · NHLBI · RBHS-NEW JERSEY MEDICAL SCHOOL · PI GONZALEZ, JAMES PATRICK · 2013 to 2015
$111k
NHLBI NIH HHS F31 HL117621NHLBI NIH HHS R21 HL094905NINDS NIH HHS P30 NS046593
6 · The paper itself

Abstract

The Inhibitor of DNA Binding (Id) proteins play a crucial role in regulating hematopoiesis and are known to interact with E proteins and the bHLH family of transcription factors. Current efforts seek to elucidate the individual roles of Id members in regulating hematopoietic development and specification. However, the nature of their functional redundancies remains elusive since ablation of multiple Id genes is embryonically lethal. We developed a model to test this compensation in the adult. We report that global Id3 ablation with Tie2Cre-mediated conditional ablation of Id1 in both hematopoietic and endothelial cells (Id cDKO) extends viability to 1 year but leads to multi-lineage hematopoietic defects including the emergence of anemia associated with defective erythroid development, a novel phenotype unreported in prior single Id knockout studies. We observe decreased cell counts in the bone marrow and splenomegaly to dimensions beyond what is seen in single Id knockout models. Transcriptional dysregulation of hematopoietic regulators observed in bone marrow cells is also magnified in the spleen. E47 protein levels were elevated in Id cDKO bone marrow cell isolates, but decreased in the erythroid lineage. Chromatin immunoprecipitation (ChIP) studies reveal increased occupancy of E47 and GATA1 at the promoter regions of β-globin and E2A. Bone marrow transplantation studies highlight the importance of intrinsic Id signals in maintaining hematopoietic homeostasis while revealing a strong extrinsic influence in the development of anemia. Together, these findings demonstrate that loss of Id compensation leads to dysregulation of the hematopoietic transcriptional network and multiple defects in erythropoietic development in adult mice.

Indexed as

AnemiaGene DeletionAnimalsErythropoiesisGATA1 Transcription FactorHematopoietic Stem CellsHumansHuman Umbilical Vein Endothelial CellsInhibitor of Differentiation Protein 1Inhibitor of Differentiation ProteinsMiceMice, KnockoutTranscription Factor 3Gata1 protein, mouseGATA1 Transcription FactorIdb1 protein, mouseIdb3 protein, mouseInhibitor of Differentiation Protein 1Inhibitor of Differentiation ProteinsTranscription Factor 3

Identifiers

PMID27128622
PMCPMC4851361
OpenAlexW2342722466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.